Antigens, CD7 ; metabolism ; Burkitt Lymphoma ; immunology ; pathology ; CD3 Complex ; metabolism ; Child ; Child, Preschool ; Diagnosis, Differential ; Female ; Humans ; Ki-67 Antigen ; metabolism ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; immunology ; pathology ; Sarcoma, Myeloid ; immunology ; pathology

Carcinoma, Intraductal, Noninfiltrating ; therapy ; Humans ; Lymphoma ; therapy ; Periodicals as Topic ; standards ; Practice Guidelines as Topic ; standards ; Publishing ; standards

Burkitt Lymphoma ; pathology ; virology ; Epstein-Barr Virus Infections ; pathology ; Hematologic Diseases ; pathology ; Histiocytic Necrotizing Lymphadenitis ; pathology ; Hodgkin Disease ; pathology ; Humans ; Lymphoma ; classification ; pathology

Cyclin D1 ; metabolism ; Gene Rearrangement ; Germinal Center ; metabolism ; pathology ; Humans ; Lymphoma ; genetics ; metabolism ; pathology ; Lymphoma, Follicular ; genetics ; metabolism ; pathology ; Lymphoma, Mantle-Cell ; genetics ; metabolism ; pathology ; Proto-Oncogene Proteins c-bcl-2 ; metabolism

Humans ; Lymphoma ; classification ; pathology ; Lymphoma, B-Cell ; classification ; pathology ; Lymphoma, T-Cell ; classification ; pathology ; Lymphoproliferative Disorders ; pathology ; Pseudolymphoma ; pathology ; Skin Neoplasms ; classification ; pathology ; World Health Organization

Objective:To explore the seizure recurrence and prognosis of epilepsy in relapse after anti-epileptic drugs (AEDs) withdrawal, and the influencing factors for these conditions.Methods:From December 2009 to August 2018, patients from the Affiliated Brain Hospital of Nanjing Medical University who relapsed after AEDs withdrawal were collected and followed up for at least 18 months. The seizure recurrence and prognosis of these patients were prospectively observed. The Kaplan-Meier method was used for survival analysis. The associated risk factors of the second relapse in the enrolled patients were analyzed by multivariate Cox analysis. The included patients were divided into good prognosis group and poor prognosis group according to whether they had achieved seizure freedom for at least one year after the first relapse. A multivariate Cox regression model was used to analyze the independent risk factors affecting their prognosis.Results:A total of 56 patients with epilepsy in relapse after AEDS withdrawal were collected. The average follow-up period was 46.23 months (18-120 months) from the initial time of seizure recurrence, and 21 patients (37.5%) had the second seizure recurrence. The relapsing risk in patients who continued to be observed without adding AEDs was higher than those who were treated immediately with drugs [9/16 vs 30.0% (12/40)], but without statistically significant difference (χ2=2.220, P=0.071). The results of univariate analysis showed that focal seizures, seizure frequency more than once per month before remission and poly-drug therapy before AEDs withdrawal were associated with high risk of the second relapse. Poly-drug therapy was an independent risk factor for the second relapse by multivariate Cox analysis ( HR=3.383, 95% CI 1.257-9.105). Of the 56 patients with epilepsy in relapse after AEDs withdrawal, 47 patients (83.9%) had a good prognosis without seizure for at least one year, and of 33 patients who were followed up for three years or more, 26 (78.8%) had no seizure for at least two years. Between the group retreated immediately after the first recurrence and the group without immediate treatment [87.5% (35/40) vs 12/16],there were no statistically significant differences on the proportions of good prognosis (χ2=2.333, P=0.258). Univariate analysis showed that the course of epilepsy>6 months before initial treatment, the frequency of seizures>1/month before remission, symptomatic epilepsy and poly-drug therapy were associated with the poor prognosis. However, none of independent risk factors was found for the poor prognosis through the multivariate analysis. Conclusions:The prognosis of patients with epilepsy in relapse after AEDs withdrawal is well, and about 2/3 patients with epilepsy in relapse after AEDs withdrawal have no more seizure recurrences. The poly-drug therapy before AEDs withdrawal may be an independent risk factor for the second seizure relapse.

Adolescent ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; administration & dosage ; Cyclophosphamide ; administration & dosage ; Diagnosis, Differential ; Doxorubicin ; administration & dosage ; Female ; Hodgkin Disease ; pathology ; Humans ; Lung Neoplasms ; pathology ; Lymphoma, B-Cell ; drug therapy ; pathology ; surgery ; Male ; Mediastinal Neoplasms ; drug therapy ; pathology ; surgery ; Mediastinum ; surgery ; Neoplasm Invasiveness ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; pathology ; Prednisone ; administration & dosage ; Thymoma ; pathology ; Thymus Neoplasms ; pathology ; Vincristine ; administration & dosage

Apoptosis ; Cell Line, Tumor ; Humans ; Immunophenotyping ; Killer Cells, Natural ; immunology ; Lymphoma, T-Cell ; immunology ; pathology ; Nose Neoplasms ; immunology ; pathology

Adult ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; CD56 Antigen ; metabolism ; Cyclophosphamide ; therapeutic use ; Doxorubicin ; therapeutic use ; Fever of Unknown Origin ; etiology ; Humans ; Lymphoma, Extranodal NK-T-Cell ; complications ; metabolism ; pathology ; therapy ; Male ; Prednisone ; therapeutic use ; Splenectomy ; Splenic Neoplasms ; complications ; metabolism ; pathology ; therapy ; Vincristine ; therapeutic use ; Young Adult

Antiviral Agents ; therapeutic use ; Castleman Disease ; drug therapy ; metabolism ; pathology ; virology ; Dendritic Cells, Follicular ; pathology ; Herpesviridae Infections ; virology ; Herpesvirus 8, Human ; isolation & purification ; Humans ; Interleukin-6 ; blood ; Receptor, Epidermal Growth Factor ; metabolism